H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 10, H.C. Wainwright reiterated the Buy rating on ImmunityBio, Inc. (NASDAQ:IBRX), keeping the price target at $8.

Andres Y. Maldonado from H.C. Wainwright reaffirmed the rating on IBRX after the company announced promising developments with ANKTIVA in treating advanced non-small cell lung cancer (NSCLC). On September 8, ImmunityBio reported that the new paradigm-changing findings from the Phase 2 study showed that ANKTIVA reverses low natural killer and T cells in patients with checkpoint inhibitor-resistant advanced NSCLC.

H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8

The study found that 60% of the patients experienced reversal from lymphopenia, with 80% maintaining an absolute lymphocyte count (ALC) above 1,200 cells/uL. The results demonstrate significant improvements in survival rates among lymphopenia survivors. ANKTIVA’s immune reconstitution approach may have broader applications across different tumor types. ANKTIVA’s established presence in bladder cancer and ongoing developments in other malignancies make it a versatile and promising cytokine therapy. Maldonado’s positive take on ImmunityBio indicates the company’s optimistic outlook for its role in oncology.

ImmunityBio, Inc. (NASDAQ:IBRX) is a commercial-stage biotechnology firm that develops next-generation therapies that bolster the natural immune system to overcome cancers and infectious diseases.

While we acknowledge the potential of IBRX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IBRX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.